Publication:
Validation of the D: A: D Chronic Kidney Disease Risk Score Model Among People Living With HIV in the Asia-Pacific

dc.contributor.authorWin Min Hanen_US
dc.contributor.authorRimke Bijkeren_US
dc.contributor.authorEzhilarasi Chandrasekaranen_US
dc.contributor.authorSanjay Pujarien_US
dc.contributor.authorOon Tek Ngen_US
dc.contributor.authorPenh Sun Lyen_US
dc.contributor.authorMan Po Leeen_US
dc.contributor.authorKinh Van Nguyenen_US
dc.contributor.authorYu Jiun Chanen_US
dc.contributor.authorCuong Duy Doen_US
dc.contributor.authorJun Yong Choien_US
dc.contributor.authorRomanee Chaiwarithen_US
dc.contributor.authorTuti Parwati Meratien_US
dc.contributor.authorSasisopin Kiertiburanakulen_US
dc.contributor.authorIskandar Azwaen_US
dc.contributor.authorSuwimon Khusuwanen_US
dc.contributor.authorFujie Zhangen_US
dc.contributor.authorYasmin Mohamed Ganien_US
dc.contributor.authorJunko Tanumaen_US
dc.contributor.authorShashikala Sangleen_US
dc.contributor.authorRossana Ditangcoen_US
dc.contributor.authorEvy Yunihastutien_US
dc.contributor.authorJeremy Rossen_US
dc.contributor.authorAnchalee Avihingsanonen_US
dc.contributor.otherHospital Sungai Bulohen_US
dc.contributor.otherBeijing Ditan Hospital Capital Medical Universityen_US
dc.contributor.otherVHS Medical Centre Indiaen_US
dc.contributor.otherGokilaen_US
dc.contributor.otherBach Mai Hospitalen_US
dc.contributor.otherUniversitas Udayanaen_US
dc.contributor.otherUniversity of Indonesia, RSUPN Dr. Cipto Mangunkusumoen_US
dc.contributor.otherChulalongkorn Universityen_US
dc.contributor.otherKirby Instituteen_US
dc.contributor.otherNational Center for Global Health and Medicineen_US
dc.contributor.otherThe HIV Netherlands Australia Thailand Research Collaborationen_US
dc.contributor.otherYonsei University College of Medicineen_US
dc.contributor.otherFaculty of Medicine, Ramathibodi Hospital, Mahidol Universityen_US
dc.contributor.otherQueen Elizabeth Hospital Hong Kongen_US
dc.contributor.otherUniversity of Malaya Medical Centreen_US
dc.contributor.otherVeterans General Hospital-Taipeien_US
dc.contributor.otherTan Tock Seng Hospitalen_US
dc.contributor.otherBJ Government Medical College and Sassoon General Hospitalsen_US
dc.contributor.otherNational Hospital for Tropical Diseasesen_US
dc.contributor.otheramfAR - The Foundation for AIDS Researchen_US
dc.contributor.otherResearch Institute for Health Sciencesen_US
dc.contributor.otherInstitute of Infectious Diseasesen_US
dc.contributor.otherChiangrai Prachanukroh Hospitalen_US
dc.contributor.otherNational Center for HIV/AIDSen_US
dc.date.accessioned2020-11-18T09:54:33Z
dc.date.available2020-11-18T09:54:33Z
dc.date.issued2020-12-01en_US
dc.description.abstractBACKGROUND: We validated the Data collection on Adverse events of anti-HIV Drugs (D:A:D) full-risk and short-risk score models for chronic kidney disease (CKD) in the Asian HIV cohorts. SETTINGS: A validation study among people living with HIV (PLHIV) aged ≥18 years among the cohorts in the Asia-Pacific region. METHODS: PLHIV with a baseline estimated glomerular filtration rate > 60 mL/min/1.73 m were included for validation of the D:A:D CKD full version and short version without cardiovascular risk factors. Those with <3 estimated glomerular filtration rate measurements from baseline or previous exposure to potentially nephrotoxic antiretrovirals were excluded. Kaplan-Meier methods were used to estimate the probability of CKD development. The area under the receiver operating characteristics was also used to validate the risk score. RESULTS: We included 5701 participants in full model {median 8.1 [interquartile range (IQR) 4.8-10.9] years follow-up} and 9791 in short model validation [median 4.9 (IQR 2.5-7.3) years follow-up]. The crude incidence rate of CKD was 8.1 [95% confidence interval (CI): 7.3 to 8.9] per 1000 person-years in the full model cohort and 10.5 (95% CI: 9.6 to 11.4) per 1000 person-years in the short model cohort. The progression rates for CKD at 10 years in the full model cohort were 2.7%, 8.9%, and 26.1% for low-risk, medium-risk, and high-risk groups, and 3.5%, 11.7%, and 32.4% in the short model cohort. The area under the receiver operating characteristics for the full-risk and short-risk score was 0.81 (95% CI: 0.79 to 0.83) and 0.83 (95% CI: 0.81 to 0.85), respectively. CONCLUSION: The D:A:D CKD full-risk and short-risk score performed well in predicting CKD events among Asian PLHIV. These risk prediction models may be useful to assist clinicians in identifying individuals at high risk of developing CKD.en_US
dc.identifier.citationJournal of acquired immune deficiency syndromes (1999). Vol.85, No.4 (2020), 489-497en_US
dc.identifier.doi10.1097/QAI.0000000000002464en_US
dc.identifier.issn19447884en_US
dc.identifier.other2-s2.0-85095399729en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/60025
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85095399729&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleValidation of the D: A: D Chronic Kidney Disease Risk Score Model Among People Living With HIV in the Asia-Pacificen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85095399729&origin=inwarden_US

Files

Collections